Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE ® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134063

Published: 2020

Journal Articles

First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network

Giovanni Palladini, MD PhD, Stefan Schönland, MD, Giampaolo Merlini, MD, Paolo Milani, MDPhD, Arnaud Jaccard, MD PhD, Frank Bridoux, MD PhD, Wilfried Roeloffzen, MD PhD, M. Teresa Cibeira, MD PhD, Hermine Agis, MD, Monique C. Minnema, MD PhD, Rui Bergantim, MD, Roman Hajek, MD PhD, Cristina João, MD PhD MSc, Ashutosh D. Wechalekar, MBBS,FRCP,FRCPath,DM, Pieter Sonneveld, MD PhD, Efstathios Kastritis, MD

Blood (2020) 136 (Supplement 1): 50–51.

https://doi.org/10.1182/blood-2020-140708

Published: 2020

Journal Articles

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Ajai Chari, MD, Jesus G. Berdeja, MD, Albert Oriol, Niels W. C. J. van de Donk, MD, Paula Rodriguez, Elham Askari, Maria-Victoria Mateos, MD PhD, Monique C. Minnema, MD PhD, Raluca Verona, PhD, Suzette Girgis, PhD BPharm, MS, Thomas Prior, Brandi W. Hilder, PhD, Jeffery Russell, MD PhD, Jenna D. Goldberg, MD, Amrita Krishnan, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-133873

Published: 2020

Journal Articles

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

Blood (2019) 134 (Supplement_1): 692.

https://doi.org/10.1182/blood-2019-123143

Published: 2019

Journal Articles

Platelet RNA Splicing Profiles Can Distinguish IgM MGUS Patients from Healthy Individuals

Mick J.M. Van Eijs, MSc, Nicolette C. Notermans, MD PhD, Tom Würdinger, PhD, Monique C. Minnema, MD PhD

Blood (2019) 134 (Supplement_1): 3771.

https://doi.org/10.1182/blood-2019-124325

Published: 2019

Journal Articles

Long-Lasting Remissions for Myeloma Patients on Daratumumab Therapy from the GEN501 and GEN503 Trials

Agoston Gyula Szabo, MD, Monique C Minnema, MD PhD, Hareth Nahi, MD PhD, Torben Plesner, MD DSc

Blood (2018) 132 (Supplement 1): 3308.

https://doi.org/10.1182/blood-2018-99-111095

Published: 2018

Journal Articles

MCL-1 Inhibition Is Highly Effective Against Multiple Myeloma Cells from Poor Prognosis Patients

Anne Slomp, MSc, Laura M Moesbergen, Constantijn J.M. Halkes, MD, Pieter Sonneveld, MD PhD, Monique C Minnema, MD PhD, Victor Peperzak, PhD MSc

Blood (2018) 132 (Supplement 1): 1916.

https://doi.org/10.1182/blood-2018-99-117990

Published: 2018

Journal Articles

Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial

Pieter Sonneveld, MDPhD, Sonja Zweegman, MDPhD, Michele Cavo, MD, Kazem Nasserinejad, PhD, Rosella Troia, Ludek Pour, MD, Sandra Croockewit, MD, Paolo Corradini, MD, Francesca Patriarca, MD, Kalung Wu, MD, Jolanda Droogendijk, MD, Annemiek Broyl, MD PhD, Monique C Minnema, MD PhD, Bruno Costa, Karim Saad Iskander, MD, Mario Boccadoro, MD

Blood (2018) 132 (Supplement 1): 801.

https://doi.org/10.1182/blood-2018-99-114029

Published: 2018

Journal Articles

First Results of a Prospective I/II Clinical Trial in Adult Patients Using TCR Alpha/Beta Depleted Stem Cell Transplantation from Matched Related and Unrelated Donors

Moniek De Witte, MD PhD, Anna Van Rhenen, MD PhD, Geerte Van Sluis, MD PhD, Rick Admiraal, MD PhD, Lotte van der Wagen, MD, Eefke J. Petersen, MD PhD, Reinier Raymakers, MD PhD, Monique C Minnema, MD PhD, Anke Janssen, MD, Kasper Westinga, BSc, Constantijn J.M. Halkes, MD, J.H. Frederik Falkenburg, MD PhD, Jaap Jan Boelens, MD PhD, Jurgen Kuball, MD

Blood (2018) 132 (Supplement 1): 2164.

https://doi.org/10.1182/blood-2018-99-112758

Published: 2018

Journal Articles

Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, PhD, Mark-David Levin, MDPhD, Saskia K. Klein, MD PhD, Esther de Waal, PhD, Corien Eeltink, Charlotte L.B.M. Korst, MD, Paula F Ypma, MDPhD, Amanda C. Dijk, MD, Matthijs Westerman, MD, Wendy Deenik, MD, Bea Tanis, PhD, Monique C Minnema, MD PhD, Henk M.W. Verheul, MD PhD, Birgit I. Lissenberg-Witte, PhD, Niels WCJ van de Donk, MD PhD, Pieter Sonneveld, MD PhD, Sonja Zweegman, MD PhD

Blood (2018) 132 (Supplement 1): 1889.

https://doi.org/10.1182/blood-2018-99-116920

Published: 2018

Journal Articles

Bortezomib Maintenance Therapy after Induction with R-CHOP, ARA-C and Autologous Stem Cell Transplantation in Newly Diagnosed MCL Patients, Results of a Multicenter Phase II HOVON Study

Jeanette K Doorduijn, MD PhD, Monique C. Minnema, MD PhD, Marie Jose Kersten, MD PhD, Pieternella J Lugtenburg, MD PhD, Martin R. Schipperus, MD PhD, Marinus van Marwijk Kooy, MD PhD, Marius MacKenzie, MD PhD, Josée M Zijlstra, MD, Henriette W Berenschot, MD, M. R Schaafsma, MD PhD, Dana A Chitu, PhD, Hanneke C. Kluin-Nelemans, MD PhD

Blood (2015) 126 (23): 339.

https://doi.org/10.1182/blood.V126.23.339.339

Published: 2015

Journal Articles

Genetic Mutational Panel Analyses of Extramedullary Relapses in Multiple Myeloma; No Gain of RAS Mutations

Monique C. Minnema, MD PhD, Sanne de Haart, MD, Tuna Mutis, MD PhD, Marco Koudijs, PhD, Marja van Blokland, Henk Lokhorst, MD PhD, Roel de Weger, MD PhD, Stefan Willems, MD PhD

Blood (2015) 126 (23): 4174.

https://doi.org/10.1182/blood.V126.23.4174.4174

Published: 2015

Journal Articles

Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma

Torben Plesner, MD, Tobias Arkenau, MD, Henk Lokhorst, Peter Gimsing, MD, DMSci, Jakub Krejcik, MD, Charlotte Lemech, MD, Monique C. Minnema, MD PhD, Ulrik Lassen, MD PhD, Andrew Cakana, FRCPath, MD, Nikolai Constantin Brun, MD PhD, Linda Basse, MD DMSc, Antonio Palumbo, MD, Paul G. Richardson, MD

Blood (2013) 122 (21): 1986.

https://doi.org/10.1182/blood.V122.21.1986.1986

Published: 2013

Journal Articles

No Improvement Of Overall Survival After Extended Follow-Up Of Donor Versus No Donor Analysis Of Newly Diagnosed Myeloma Patients Included In The HOVON 50/54 Study

Henk Lokhorst, Bronno van der Holt, PhD, Jan Cornelissen, MD, PhD, Marie José Kersten, MD, PhD, Marinus H.J. Van Oers, MD, PhD, Reinier Raymakers, MD, PhD, Monique C. Minnema, MD PhD, Sonja Zweegman, MD PhD, Jeroen JWM Janssen, MD, Mark Zijlmans, MD, Gerard M.J. Bos, Prof MD PhD, Nicolaas PM Schaap, MD, PhD, Okke de Weerdt, Shulamiet Wittebol, MD, Rianne Ammerlaan, Pieter Sonneveld, MD, Ph.D

Blood (2013) 122 (21): 2132.

https://doi.org/10.1182/blood.V122.21.2132.2132

Published: 2013

Journal Articles

The Survivin Suppressant YM155 Overcomes Microenvironment-Mediated Immune Resistance In a Humanized Multiple Myeloma Mouse Model

Sanne J. de Haart, MD, Monique C. Minnema, MD PhD, Julie H. Huang, PhD, Tineke Aarts-Riemens, Henk Lokhorst, Anton Martens, PhD, Constantine S. Mitsiades, MD, PhD, Tuna Mutis, MD, PhD

Blood (2013) 122 (21): 3250.

https://doi.org/10.1182/blood.V122.21.3250.3250

Published: 2013

Journal Articles

Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial

Henk Lokhorst, Bronno van der Holt, PhD, Sonja Zweegman, MD PhD, Edo Vellenga, MD, PhD, Sandra Croockewit, MD, Marinus H.J. Van Oers, MD, PhD, Peter von dem Borne, MD, PhD, Pierre W. Wijermans, MD, PhD, M. R Schaafsma, MD, PhD, Okke de Weerdt, Shulamiet Wittebol, MD, Michel Delforge, MD, PhD, Gerard M.J. Bos, Prof MD PhD, Harm Sinnige, Marinus MarwijkKooy, Peter Joosten, MD, Monique C. Minnema, MD PhD, Rianne Ammerlaan, Pieter Sonneveld, MD, Ph.D

Blood (2013) 122 (21): 3332.

https://doi.org/10.1182/blood.V122.21.3332.3332

Published: 2013

Journal Articles

Microenvironment Shields Myeloma From Adoptive Immunotherapy by Cell Adhesion Mediated Immune Resistance (CAM-IR),

Sanne J de Haart, MD, Monique C. Minnema, MD PhD, Tineke Aarts-Riemens, Niels Bovenschen, PhD, Henk M. Lokhorst, MD, Tuna Mutis, MD PhD

Blood (2011) 118 (21): 4039.

https://doi.org/10.1182/blood.V118.21.4039.4039

Published: 2011

Journal Articles

Platelet Doubling After the First Azacitidine Cycle Is a Promising Predictor for Response in MDS, CMML and AML Patients in the Dutch Azacitidine Compassionate Patient Named Program,

Blood (2011) 118 (21): 3841.

https://doi.org/10.1182/blood.V118.21.3841.3841

Published: 2011

Journal Articles

Identification of New Hematopoietic Minor Histocompatibility Antigen UTA2-1; Ready for Application in Antitumor Immunotherapy

Rimke Oostvogels, MD, Monique C. Minnema, MD PhD, Maureen van Elk, Robbert M Spaapen, PhD, Debbie van Baarle, PhD, Eric Spierings, PhD, Henk M. Lokhorst, MD, Tuna Mutis, MD PhD

Blood (2011) 118 (21): 2979.

https://doi.org/10.1182/blood.V118.21.2979.2979

Published: 2011

Journal Articles

Lenalidomide Maintenance Following Non Myeloablative Allogeneic Stem Cell Transplantation In Patients with Multiple Myeloma: Results of the HOVON 76 Study

Monique C. Minnema, MD, PhD, Evelien Kneppers, MD, Ronnie van Der Holt, PhD, Marie Jose Kersten, MD, PhD, Sonja Zweegman, MD, PhD, Ellen Meijer, MD, PhD, Edo Vellenga, MD, PhD, Tuna Mutis, MD, PhD, Petra Cornelisse, Henk Lokhorst, MD, PhD

Blood (2010) 116 (21): 3502.

https://doi.org/10.1182/blood.V116.21.3502.3502

Published: 2010

NARROW

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE ® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

First Glimpse on Real-World Efficacy Outcomes for 2000 Patients with Systemic Light Chain Amyloidosis in Europe: A Retrospective Observational Multicenter Study By the European Myeloma Network

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study

Platelet RNA Splicing Profiles Can Distinguish IgM MGUS Patients from Healthy Individuals

Long-Lasting Remissions for Myeloma Patients on Daratumumab Therapy from the GEN501 and GEN503 Trials

MCL-1 Inhibition Is Highly Effective Against Multiple Myeloma Cells from Poor Prognosis Patients

Carfilzomib, Pomalidomide and Dexamethasone (KPd) in Patients with Multiple Myeloma Refractory to Bortezomib and Lenalidomide. the EMN011 Trial

First Results of a Prospective I/II Clinical Trial in Adult Patients Using TCR Alpha/Beta Depleted Stem Cell Transplantation from Matched Related and Unrelated Donors

Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study

Bortezomib Maintenance Therapy after Induction with R-CHOP, ARA-C and Autologous Stem Cell Transplantation in Newly Diagnosed MCL Patients, Results of a Multicenter Phase II HOVON Study

Genetic Mutational Panel Analyses of Extramedullary Relapses in Multiple Myeloma; No Gain of RAS Mutations

Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma

No Improvement Of Overall Survival After Extended Follow-Up Of Donor Versus No Donor Analysis Of Newly Diagnosed Myeloma Patients Included In The HOVON 50/54 Study

The Survivin Suppressant YM155 Overcomes Microenvironment-Mediated Immune Resistance In a Humanized Multiple Myeloma Mouse Model

Thalidomide Combined With High Dose Melphalan Improves Event Free and Overall Survival In Patients With Newly Diagnosed Multiple Myeloma: Extended Follow-Up Of The HOVON-50 Trial

Microenvironment Shields Myeloma From Adoptive Immunotherapy by Cell Adhesion Mediated Immune Resistance (CAM-IR),

Platelet Doubling After the First Azacitidine Cycle Is a Promising Predictor for Response in MDS, CMML and AML Patients in the Dutch Azacitidine Compassionate Patient Named Program,

Identification of New Hematopoietic Minor Histocompatibility Antigen UTA2-1; Ready for Application in Antitumor Immunotherapy

Lenalidomide Maintenance Following Non Myeloablative Allogeneic Stem Cell Transplantation In Patients with Multiple Myeloma: Results of the HOVON 76 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only